论文部分内容阅读
报道1例垂体促甲腺激素(TSH)腺瘤用生长激素释放抑制因子类似物Saudostatine(SMS 201-995 Sandoz)治疗7个月的结果。病人26岁女性,8年前因甲亢、垂体大腺瘤Ⅲ级伴头痛、视力减退、泌乳、左Ⅵ麻痹住院经蝶窦垂体瘤肉眼全切除术,术前血PRL28ng/ml,TSH11mU/1,T_4138ng/ml(正常<115)。病理:光镜嫌色性;免疫组化,扰血清抗-TSH 反应(-)。术后继以放疗(~(60)Co50Grays)。术后一年半TSH1mU/ml,T_4正常,TRH 兴奋试验(+)。术后7年又出现甲亢伴甲状腺肿大,无突眼。FT_471pmol/1(正常<27),FT_322pmol/1(正常<10),TSH5.35mU/1(正常0.1～4)。α309μPg/1(正常<105μg/1),TRH 兴奋试验
One case of pituitary thyroid hormone (TSH) adenoma was treated with saludostatine (SMS 201-995 Sandoz), a growth hormone releasing inhibitor analog, for 7 months. Patients 26-year-old female, eight years ago due to hyperthyroidism, pituitary adenoma grade III headache, vision loss, lactation, left VI palsy sinus pituitary tumor resection of the naked eye, preoperative blood PRL 28ng/ml, TSH11mU/1, T_4138 ng/ml (normal <115). Pathology: chromophobe by light microscopy; immunohistochemistry, interfering serum anti-TSH response (-). Followed by radiotherapy (~(60)Co50Grays). One and a half years after surgery, TSH1mU/ml, T_4 normal, TRH stimulation test (+). After 7 years, there was hyperthyroidism with goiter, no exophthalmos. FT_471 pmol/1 (normal <27), FT_322 pmol/1 (normal <10), TSH 5.35 mU/1 (normal 0.1 to 4). α309μPg/1 (normal <105μg/1), TRH stimulation test